Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT)

K Gordon; RB Warren; AB Gottlieb; A Blauvelt; D Tha?i; Y Poulin; M Boehnlein; F Brock; C Arendt; K Reich

doi:10.25251/skin.4.supp.81

K Gordon

Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI

RB Warren

Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, UK

AB Gottlieb

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

A Blauvelt

Oregon Medical Research Center, Portland, OR

D Tha?i

Institute and Comprehensive Center for Inflammation Medicine, University of L?beck, L?beck, Germany

Y Poulin

Centre de Recherche Dermatologique du Qu?bec M?tropolitain, Qu?bec, Canada

M Boehnlein

UCB Pharma, Monheim am Rhein, Germany

F Brock

UCB Pharma, Slough, UK

C Arendt

UCB Pharma, Brussels, Belgium

K Reich

Centre for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf and Skinflammation? Center, Hamburg, Germany

Keywords

Psoriasis, Plaque Psoriasis, Biologic, Certolizumab, Efficacy

Abstract

Abstract not available.

References

1. Parisi R. J Invest Dermatol 2013;133:377–85

2. Certolizumab Pegol Prescribing Information. Available at http://www.accessdata.fda.gov

3. Certolizumab Pegol Summary of Product Characteristics. Available at http://www.ema.europa.eu/ema

4. Gottlieb AB. JAAD 2018;79:302–14; 5Lebwohl M. JAAD 2018;79:266–76.

Poster PDF

Published

Oct 27, 2020

DOI https://doi.org/10.25251/skin.4.supp.81

How to Cite

Gordon, K., Warren, R., Gottlieb, A., Blauvelt, A., Tha?i, D., Poulin, Y., Boehnlein, M., Brock, F., Arendt, C., & Reich, K. (2020). Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT). SKIN The Journal of Cutaneous Medicine, 4(6), s81. https://doi.org/10.25251/skin.4.supp.81

Issue

Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)

Section

Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

A Blauvelt, RB Warren, K Reich, et al., Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 2 (2019)
K Gordon, R.B. Warren, A.B. Gottlieb, A Blauvelt, D Thaci, C Leonardi, Y Poulin, M Boehnlein, S Kavanagh, C Arendt, K Reich, Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
A Blauvelt, C Paul, P van de Kerkhof, RB Warren, AB Gottlieb, RG Langley, F Brock, C Arendt, M Boehnlein, M Lebwohl, K Reich, Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
A Blauvelt, A Armstrong, P Rich, R Kisa, A Guana, X Meng, K Callis Duffin, Secukinumab Provides Complete or Almost-Complete Psoriasis Clearance in Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of 4 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
M Augustin, J Wegtowska, M Lebwohl, C Paul, V Piguet, H Sofen, A Blauvelt, L Peterson, C Arendt, R Rolleri, Clinical Response in Plaque Psoriasis Patients Switching from Etanercept to Certolizumab Pegol in a Phase 3, Randomized, Controlled Study , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
P van de Kerkhof, A Pinter, M Boehnlein, S Kavanagh, J.J. Crowley, Efficacy of Certolizumab Pegol for Psoriasis of the Head and Neck in Two Phase 3 Clinical Trials: CIMPASI-1 and CIMPASI-2 , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
K Gordon, K Papp, M Gooderman, D Thaci, P Foley, A Morita, S Kundu, R Kisa, A Napoli, S Banerjee, Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
D Thaçi, A Armstrong, M Lebwohl, A Blauvelt, C Paul, L Puig, M Wang, V Vanvoorden, C Madden, S Wiegratz, D Deherder, KB Gordon, Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
AB Gottlieb, P Gisondi, J Eells, L Peterson, A Kavanaugh, Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
A Armstrong, RG Langley, KB Gordon, RB Warren, D Thaçi, L Stein Gold, L Peterson, C Madden, N Nunez Gomez, D de Cuyper, A Costanzo, Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®

<< < 1 2 3 4

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)